Delcath Systems, Inc. (NASDAQ:DCTH) Receives Average Recommendation of “Hold” from Analysts

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have earned an average recommendation of “Hold” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $22.50.

A number of brokerages recently issued reports on DCTH. Zacks Research downgraded Delcath Systems from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Wall Street Zen downgraded Delcath Systems from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Evercore set a $27.00 price target on Delcath Systems in a report on Thursday, February 26th. BTIG Research lowered their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Finally, Weiss Ratings raised Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday.

Delcath Systems Stock Down 3.4%

Shares of DCTH opened at $11.07 on Friday. The stock has a 50 day moving average price of $10.13 and a 200 day moving average price of $9.85. The company has a market capitalization of $382.14 million, a price-to-earnings ratio of 1,107.00 and a beta of 0.54. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $18.23.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.07. The firm had revenue of $24.99 million during the quarter, compared to the consensus estimate of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. On average, equities analysts anticipate that Delcath Systems will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

Several large investors have recently modified their holdings of DCTH. California State Teachers Retirement System acquired a new stake in shares of Delcath Systems in the second quarter valued at approximately $26,000. Russell Investments Group Ltd. acquired a new stake in shares of Delcath Systems in the third quarter valued at approximately $29,000. Tower Research Capital LLC TRC acquired a new stake in shares of Delcath Systems in the second quarter valued at approximately $40,000. Legal & General Group Plc acquired a new stake in shares of Delcath Systems in the second quarter valued at approximately $46,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Delcath Systems in the second quarter valued at approximately $151,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.